Formulation | ANOVA for Significant Differences* | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
A | B | C | D | E | F | G | ||||||||
Rate of total FA transport in lymph (μmol/h) | 13.5 ± 1.0 | 19.1 ± 0.6 | 32.5 ± 0.8 | 29.3 ± 0.7 | 49.8 ± 1.3 | 55.7 ± 2.3 | 64.4 ± 0.6 | |||||||
TG-associated FA (μmol/h) | 10.3 ± 0.8 | 16.7 ± 2.5 | 25.5 ± 0.8 | 24.3 ± 0.8 | 44.7 ± 1.2 | 49.7 ± 2.1 | 57.2 ± 0.6 | |||||||
PL-associated FA (μmol/h) | 3.2 ± 0.2b,d | 2.5 ± 0.1a | 7.0 ± 0.3g | 5.0 ± 0.2a,e,f | 5.1 ± 0.1d,f | 6.0 ± 0.2d,e,g | 7.2 ± 0.3c,f | See footnote | ||||||
Rate of endogenous FA transport in lymph (μmol/h) | 13.5 ± 1.0 | 12.1 ± 0.6 | 28.7 ± 0.6 | 22.1 ± 0.9 | 17.7 ± 1.3 | 19.2 ± 0.9 | 18.9 ± 0.9 | |||||||
Rate of exogenous FA transport in lymph (μmol/h) | N.A. | 7.0 ± 0.2 | 3.8 ± 0.3 | 7.1 ± 0.2 | 32.1 ± 1.2 | 36.4 ± 2.2 | 45.4 ± 0.3 | |||||||
Proportion (%) of the exogenous FA dose transported into the lymph | N.A. | 39.6 ± 1.1d,e | 53.1 ± 4.0f | 40.5 ± 1.4b,e | 45.4 ± 1.7b,d,f | 51.5 ± 3.1c,e | 64.2 ± 0.4 | See footnote |
a, b, c, d, e, f, g The parameter is not significantly different (P > 0.05) to formulations A, B, C, D, E, F, and G, respectively.
↵* Formulations grouped by bars are not significantly different (P > 0.05).